SAREPTA THERAPEUTICS

Sarepta Therapeutics Prices $1.0 Billion of Convertible Senior Notes Due 2027

14 Sep 2022 04:00:25 By Nasdaq GlobeNewswire

Sarepta Therapeutics Announces Proposed Offering of $1.0 Billion of Convertible Senior Notes Due 2027

12 Sep 2022 13:41:31 By Nasdaq GlobeNewswire

Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2022-2023 Academic Year

07 Sep 2022 05:30:01 By Nasdaq GlobeNewswire

Sarepta Therapeutics to Present at the Morgan Stanley 20th Annual Global Healthcare Conference

06 Sep 2022 05:45:00 By Nasdaq GlobeNewswire

Sarepta Therapeutics Announces That FDA has Lifted its Clinical Hold on SRP-5051 for the Treatment of Duchenne Muscular Dystrophy

06 Sep 2022 05:30:00 By Nasdaq GlobeNewswire

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

31 Aug 2022 14:59:49 By Nasdaq GlobeNewswire

Sarepta Therapeutics Announces Progress on the MyoAAV Program and Exclusive Licensing Agreement with The Broad Institute for MyoAAV Next-generation Capsids for Rare Genetic Diseases

08 Aug 2022 05:30:00 By Nasdaq GlobeNewswire

Sarepta Therapeutics Announces Second Quarter 2022 Financial Results and Recent Corporate Developments

02 Aug 2022 13:05:01 By Nasdaq GlobeNewswire

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

29 Jul 2022 15:25:00 By Nasdaq GlobeNewswire

Sarepta Therapeutics Announces Intent to Submit an Accelerated Approval Biologics License Application for its Gene Therapy SRP-9001 to Treat Duchenne Muscular Dystrophy

29 Jul 2022 04:00:00 By Nasdaq GlobeNewswire

Sarepta Therapeutics to Announce Second Quarter 2022 Financial Results and Recent Corporate Developments on August 2, 2022

26 Jul 2022 05:30:00 By Nasdaq GlobeNewswire

Sarepta Therapeutics’ Investigational Gene Therapy SRP-9001 for Duchenne Muscular Dystrophy Demonstrates Significant Functional Improvements Across Multiple Studies

06 Jul 2022 05:15:00 By Nasdaq GlobeNewswire

Sarepta Therapeutics to Share New Clinical Data and Integrated Analysis for SRP-9001, its Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy on July 6, 2022 at 8:30am ET

05 Jul 2022 13:01:00 By Nasdaq GlobeNewswire

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

30 Jun 2022 15:15:41 By Nasdaq GlobeNewswire

Sarepta Therapeutics Provides Update on SRP-5051 for the Treatment of Duchenne Muscular Dystrophy

23 Jun 2022 13:01:00 By Nasdaq GlobeNewswire

Sarepta Therapeutics Appoints Michael Chambers and Kathryn Boor, Ph.D., to Its Board of Directors

02 Jun 2022 13:05:00 By Nasdaq GlobeNewswire

Sarepta Therapeutics to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference

02 Jun 2022 05:30:00 By Nasdaq GlobeNewswire

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

31 May 2022 15:15:23 By Nasdaq GlobeNewswire

Sarepta Therapeutics Announces First Quarter 2022 Financial Results and Recent Corporate Developments

04 May 2022 13:05:04 By Nasdaq GlobeNewswire

Sarepta Therapeutics to Present at the BofA Securities 2022 Healthcare Conference

04 May 2022 05:30:00 By Nasdaq GlobeNewswire